The Journal of Clinical Medicine retracts the article entitled “A Phase III Head-to-Head Study to Compare the Efficacy and Safety of Fexuprazan and Esomeprazole in Treating Patients with Erosive Esophagitis” [1].
Following publication, concerns were brought to the attention of the Editorial Office regarding an overlap between this publication [1] and a previous publication [2], produced by a different authorship group.
Adhering to our complaint’s procedure, an investigation was conducted by the Editorial Office and the Editorial Board that confirmed a significant similarity between the data presented in the two publications [1,2]. As a result, the Editorial Board consider this publication [1] to be redundant, and therefore have decided to retract it as per MDPI’s retraction policy (https://www.mdpi.com/ethics#_bookmark30, accessed on 22 October 2024).
This retraction was approved by the Editor-in-Chief of the Journal of Clinical Medicine.
The authors agreed to this retraction.
References
- Jeong, Y.; Lee, B.J.; Han, S.-H. RETRACTED: A Phase III Head-to-Head Study to Compare the Efficacy and Safety of Fexuprazan and Esomeprazole in Treating Patients with Erosive Esophagitis. J. Clin. Med. 2024, 13, 3262. [Google Scholar] [CrossRef] [PubMed]
- Lee, K.N.; Lee, O.Y.; Chun, H.J.; Kim, J.I.; Kim, S.K.; Lee, S.W.; Park, K.S.; Lee, K.L.; Choi, S.C.; Jang, J.Y.; et al. Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis. World J. Gastroenterol. 2022, 28, 6294–6309. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).